Obstructive sleep apnea technology developer Vivos Therapeutics has entered into a securities private purchase agreement, which is expected to gross the company about $4 million.
The deal, which is expected to close on November 2, involves the purchase and sale of approximately 980,000 shares of Vivos’ common stock at a purchase price of $4.08 per share. Vivos intends to use the net proceeds from the offering for general corporate purposes.
